Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The total mass, copy number, and distribution of hormones in the human bloodstream.

PLoS biology·2026
Same author

Toward Solar-Powered Growth of Autotrophic <i>Escherichia coli</i> Using Photoelectrochemistry.

Journal of the American Chemical Society·2026
Same author

Nine changes needed to deliver a radical transformation in biodiversity measurement.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Synthetic cells by the numbers.

iScience·2025
Same author

Rubisco is slow across the tree of life.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

The global biomass of mammals since 1850.

Nature communications·2025
Same journal

Clinical features, imaging findings, and treatment outcomes of optic neuritis associated with anti-CRMP5 antibodies: a systematic review.

Journal of neuroimmunology·2026
Same journal

Serum IDO1 and β-catenin levels in patients with multiple sclerosis with and without atherosclerosis: A case-control study.

Journal of neuroimmunology·2026
Same journal

Neurological sequelae of Long COVID: Pathophysiological mechanisms, diagnostic advances, and therapeutic perspectives.

Journal of neuroimmunology·2026
Same journal

Corrigendum to 'Role of CD40 in prion disease and the immune response to recombinant PrP' [Journal of Neuroimmunology 257 (2013) 21-27/475655].

Journal of neuroimmunology·2026
Same journal

Clinical characteristics of IgG4-related hypertrophic pachymeningitis with and without serum ANCA positivity.

Journal of neuroimmunology·2026
Same journal

Chronic neuroinflammation after acute SARS-Cov-2 infection induces retinal damage in the hACE2 transgenic mouse model.

Journal of neuroimmunology·2026
See all related articles

Related Experiment Video

Updated: Jun 6, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Combination therapy in multiple sclerosis.

Ron Milo1, Hillel Panitch

  • 1Department of Neurology, Barzilai Medical Center, 2 Hahistadrut St., Ashkelon 78278, Israel. rmilo@barzi.health.gov.il

Journal of Neuroimmunology
|November 30, 2010
PubMed
Summary
This summary is machine-generated.

Combination therapy for multiple sclerosis (MS) shows promise by combining drugs with complementary actions to improve treatment efficacy. Further research and clinical trials are needed to establish optimal drug combinations for MS management.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Related Experiment Videos

Last Updated: Jun 6, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Area of Science:

  • Neuroimmunology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) pathogenesis involves intricate neuro-immune interactions.
  • Current MS therapies offer partial effectiveness, necessitating improved treatment strategies.

Purpose of the Study:

  • To review the rationale, requirements, and evidence for combination therapy in MS.
  • To explore the potential of combining drugs with complementary mechanisms of action for enhanced therapeutic effects.

Main Methods:

  • Literature review encompassing in-vitro experiments, animal studies, and clinical trials.
  • Analysis of evidence supporting combination drug approaches in MS treatment.

Main Results:

  • Evidence from preclinical and clinical studies suggests potential additive or synergistic effects of combination therapies.
  • Current data indicates encouraging outcomes for combined drug strategies in MS.

Conclusions:

  • Combination therapy represents a promising strategy to enhance the efficacy of MS treatment.
  • Well-designed clinical trials are crucial for validating and implementing specific drug combinations in clinical practice for MS.